<DOC>
	<DOCNO>NCT00946023</DOCNO>
	<brief_summary>This phase II trial study well give fludarabine cyclophosphamide together total-body irradiation rituximab work treat patient B-cell lymphoma chronic lymphocytic leukemia undergo allogeneic ( donor ) bone marrow transplant . The type bone marrow transplant less intensive `` mini '' transplant use relative bone marrow donor . The donated bone marrow stem cell may replace patient 's immune system cell help destroy remain cancer ( graft-versus-tumor effect ) . Patients undergo type transplant often one relative could donor . The trial also study new way choose amongst possible donor might improve rituximab work .</brief_summary>
	<brief_title>Optimized Donor Selection , Nonmyeloablative BMT B-cell Lymphomas With Post-transplantation Cy Rituximab</brief_title>
	<detailed_description>This phase II relapse refractory B-cell malignancy build platform nonmyeloablative , related-donor , HLA-matched HLA-haploidentical BMT post-transplantation high-dose cyclosphosphamide administer prophylaxis graft-versus-host disease graft rejection . Rituximab add transplant regimen goal augment anti-tumor activity . In patient B-cell lymphoma , specific polymorphism immunoglobulin Fc receptor associate great sensitivity rituximab rituximab-based therapy , translate series high response rate improve progression-free survival . This raise possibility select donor carry permissive polymorphism . This trial identify select donor favorable polymorphism FcgammaR3A-158 , thereby potentially confer great sensitivity rituximab host BMT .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>Poorrisk CD20+ , Bcell lymphoma , follow : Low grade Bcell lymphoma fail least two prior therapy ( exclude single agent rituximab ) , undergone histologic conversion ( histologic conversion , PR CR require ) : 1 . Follicular grade 1 2 lymphoma 2 . Follicular lymphoma otherwise specify 3 . Marginal zone ( MALT ) lymphoma 4 . Lymphoplasmacytic lymphoma / Waldenstrom 's macroglobulinemia 5 . Hairy cell leukemia 6 . Small lymphocytic lymphoma / chronic lymphocytic leukemia ( SLL/CLL ) 7 . Low grade Bcell lymphoma , unspecified 8 . Nodular lymphocytepredominant Hodgkin lymphoma Poorrisk small lymphocytic lymphoma chronic lymphocytic leukemia , define 17p deletion , 11q deletion , histologic conversion ( histologic conversion , PR CR require ) Aggressive Bcell nonHodgkin 's lymphoma fail least one prior regimen multiagent chemotherapy , PR CR , patient either ineligible autologous hematopoietic BMT autologous BMT recommend : 1 . Follicular grade 3 lymphoma 2 . Histoconversion lowgrade Bcell lymphoma ( include SLL/CLL ) aggressive Bcell nonHodgkin 's lymphoma 3 . Mantle cell lymphoma 4 . Diffuse large Bcell lymphoma ( exclude primary CNS lymphoma ) 5 . `` Gray zone '' composite lymphoma combine feature primary mediastinal large Bcell Hodgkin 's lymphoma 6 . Burkitt 's lymphoma/leukemia 7 . Atypical Burkitt 's lymphoma/leukemia ( high grade Bcell lymphoma , unclassified , include feature intermediate Burkitt 's diffuse large Bcell lymphoma ) Must relate donor least HLA haploidentical Any previous BMT must occur least 3 month prior Left ventricular ejection fraction least 35 % Bilirubin 3.0 mg/dL ( unless due Gilbert 's syndrome ) , ALT AST 5 x upper limit normal FEV1 FVC least 40 % predict Absence uncontrolled infection More 20 % involvement bone marrow chronic lymphocytic leukemia Active central nervous system lymphoma ECOG performance status great 1 ( 2,3 , 4 ) HIV positive Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>lymphoma</keyword>
	<keyword>non hodgkin lymphoma</keyword>
	<keyword>allogeneic</keyword>
	<keyword>bone marrow transplantation</keyword>
	<keyword>nonmyeloablative</keyword>
	<keyword>cyclophosphamide</keyword>
	<keyword>rituximab</keyword>
</DOC>